Somewhere between the two-minute quiz that declares everyone a candidate and the six-month waiting list for a local psychiatrist sits the honest answer about online ADHD assessments: they are a legitimate way to get evaluated, and they are also a business model with incentives worth understanding before you type in a card number. Both things are true at once, which is why the question deserves more than a yes or a no.
It also deserves an adult framing, because ADHD assessment is no longer mostly a question about children. A CDC analysis of national survey data, published in the agency's Morbidity and Mortality Weekly Report, estimated that 15.5 million U.S. adults, about 6 percent, had a current ADHD diagnosis in 2023, and that roughly half of them received that diagnosis in adulthood. Plenty of people in their fifties and sixties recognize themselves for the first time while a grandchild is being evaluated, and the online platforms know it. Late-in-life assessment is a real clinical question and a growth market at the same time.
What telehealth genuinely fixed
The case for online assessment is access, and it is not a small case. In much of the country, adult ADHD specialists are scarce, waiting lists run months, and older adults face an extra barrier: many clinicians simply have less experience evaluating ADHD in patients over fifty, where the symptoms tangle with worries about memory and normal aging. Telehealth collapses distance, shortens waits, and for people with the very condition being assessed, removes the executive-function obstacle course of scheduling, commuting, and sitting in waiting rooms. The same CDC report found that about half of adults with ADHD had used telehealth for ADHD-related care. This is now a mainstream channel of American psychiatry rather than a fringe workaround.
A video appointment with a licensed clinician who takes a thorough history is a legitimate evaluation. The medium is fine. The variable that matters is what happens during and after the appointment, and that is where the platforms diverge.
Where the business model shows through
Many direct-to-consumer ADHD platforms are built on subscriptions. A typical arrangement charges a monthly membership, commonly in the range of $79 to $159, to remain an active patient; stop paying and the prescriptions stop. Compare that with a traditional practice, where an insured visit might involve a co-pay of $30 or less and no one bills you monthly for existing in the patient database. A subscription maintained for years can quietly pass the cost of a comprehensive in-person evaluation, which can run $2,000 or more as a one-time expense that insurance often covers in part. Some platforms do take insurance, and some issue paperwork for you to submit yourself, with no guarantee your insurer will honor it. Asking three questions before paying anything will tell you most of what you need to know: is this billed per visit or by subscription, does insurance apply, and who owns your clinical records if you leave.
The records question is the one people skip. If a platform folds or you outgrow it, a portable file documenting how your diagnosis was made is the difference between transferring care and starting over. Request visit notes and the basis for the diagnosis in writing, early, while everyone is still friendly.
Then there is the intake funnel. A screener that takes two minutes and routes every completer toward a paid diagnostic appointment is marketing wearing a stethoscope. Screening tools are supposed to screen people out as well as in. Be suspicious of any pipeline in which no answer you give slows your progress toward a billable event.
The pharmacy counter is the real gatekeeper
Whatever happens in the video call, the practical bottleneck is often the pharmacy. Among adults with ADHD who took stimulant medication in the previous year, 71.5 percent reported difficulty getting a prescription filled because the medication was unavailable, per the same CDC data. Shortages are only part of it. Pharmacists carry a legal responsibility to verify that controlled-substance prescriptions are legitimate, and some large chains have restricted filling prescriptions from certain high-volume telehealth prescribers. A diagnosis and a prescription from a platform your local pharmacy declines to work with is an expensive piece of paper.
The defensive move costs nothing but a phone call: before paying for an assessment, call the pharmacy you actually use and ask whether they fill controlled-substance prescriptions from the specific provider you are considering. Ask about stock while you are at it. People in tight markets sometimes call many pharmacies each month to find medication, and some platforms charge fees, often $20 to $30, each time a prescription must be rerouted to a different location. Those fees are absent from every advertisement you will see.
It is also worth saying plainly: medication is one tool, and for older adults it involves cardiovascular and drug-interaction considerations that deserve a real conversation with a clinician who knows your history. Stimulants are neither the only treatment for ADHD nor automatically appropriate, and an assessment whose only imaginable output is a stimulant prescription is answering a narrower question than the one you asked.
The regulatory clock everyone is renting time on
The entire remote-prescribing arrangement runs on temporary rules. Before the pandemic, federal law generally required an in-person medical evaluation before a controlled substance could be prescribed. That requirement was suspended in 2020, and the suspension has been serially extended ever since. The most recent extension, the fourth, was published in the Federal Register on the last day of 2025 and keeps the flexibilities in place through December 31, 2026.
Read that history as a weather report. The rules have been renewed each time so far, sometimes at the eleventh hour, and nothing guarantees the pattern continues or that the next version will not add in-person requirements. Some states impose their own, stricter rules on top of the federal floor. If your prescriber exists only as an app, you are exposed to every future turn of this ratchet. A hybrid arrangement, where at least one clinician within driving distance has seen you and holds your records, is insurance against a policy change you cannot control.
What a trustworthy assessment looks like
- It takes real time, typically an hour or more of clinical interview, and asks about your whole history, since ADHD symptoms begin in childhood even when the diagnosis comes decades later.
- It actively screens for the conditions that mimic or accompany ADHD. The National Institute of Mental Health notes that ADHD often co-occurs with other disorders and conditions, including learning disorders and sleep problems, and untangling those changes the treatment. In older adults, thyroid issues, depression, sleep apnea, and medication side effects belong on the list of alternatives a careful clinician rules out.
- The clinician is licensed in your state, identifiable by name, and willing to say you do not have ADHD if the evidence points that way.
- You leave with documentation you can take anywhere, and a treatment discussion broader than a single prescription.
Anything meaningfully short of that list is a screening, whatever the checkout page calls it.
A sensible path, especially later in life
Used with open eyes, an online assessment is a reasonable front door: fast, convenient, and clinically valid when the evaluation behind it is thorough. The trouble starts when it becomes the whole house. The durable strategy is to treat a platform as a bridge, keep copies of every record, confirm your pharmacy will play along before you pay, and use the time the bridge buys you to establish care with a local clinician, whether that is a psychiatrist, a primary care doctor comfortable with adult ADHD, or both. If you are past midlife and wondering whether a lifetime of scattered starts finally has a name, that question is legitimate and worth pursuing properly, with a professional who examines the alternatives and knows your health history. The companies selling two-minute certainty are answering a different question, and the product they are selling is the feeling of having asked.
